Axinn Advises Thermo Fisher Scientific in Securing Global Merger-Control Clearances for its Acquisition of Olink Holding
July 10, 2024
Axinn is pleased to represent Thermo Fisher Scientific (NYSE: TMO), a global life sciences leader, in helping obtain unconditional regulatory clearance worldwide in its $3.1 billion acquisition of Olink Holding (Nasdaq: OLK), the Swedish provider of next-generation proteomics solutions.
The team includes partners John Harkrider, Mark Alexander, and Craig Minerva, as well as associates Megan Walden, Heather Zuckert, John Bogert, and Matthew Gorski.
About Axinn
Axinn combines the skills, experience, and dedication of the world’s largest firms with the focus, responsiveness, efficiency, and attention to client needs of the best boutiques. The firm was established in the late 1990s by lawyers from premier Wall Street firms with a common vision: provide the highest level of service and strategic acumen in antitrust, intellectual property, and high-stakes litigation. Axinn’s lawyers have served as lead or co-lead counsel on more than half a trillion dollars in transactions and, in the last 10 years alone, have handled more than 500 litigations.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Informa 34th Annual Advanced EU Brussels Conference
Speaking Engagement
Antitrust
Kisaco Research Pharma and Biotech Patent Litigation Summit 2025
Speaking Engagement
Intellectual Property
GCR Live: Women in Antitrust 2025
Speaking Engagement
Antitrust
Global Legal Group Global Class Actions Symposium 2025
Speaking Engagement
Litigation & Trials
ITCTLA Mock Hearing Program 2025
Speaking Engagement
Intellectual Property
IBA Annual Conference 2025
Speaking Engagement
Antitrust
GCR Live: Global Merger Control 2025
Speaking Engagement
Antitrust
Thomson Reuters 24th Annual Law Firm COO & CFO Forum
Speaking Engagement
LegalNEXT 2025
Speaking Engagement
Antitrust
Axinn Partners Named to Lawdragon's 2026 "500 Leading Dealmakers in America" Guide
Awards & Recognitions